States Allege British Drug Company Tried to Keep Generic Suboxone Off the Market

Attorneys general from 35 states and the District of Columbia are suing a British drug company, alleging it tried to keep less expensive generic versions of the opioid addiction treatment Suboxone off the market.

The suit says the drug company, Indivior, was granted exclusive rights in 2002 to sell Suboxone tablets for seven years, Fox News reports. When those rights expired, the suit alleges, Indivior company worked with the New Jersey company MonoSol Rx to make an oral strip form of Suboxone. The strip form was marketed as safer than tablets, according to the suit. MonoSol Rx is also named in the suit.

Full story British drug company keeping Suboxone off the market at drugfree.org

HHS Will Revise Regulations on Prescribing Buprenorphine for Opioid Addiction

The Department of Health and Human Services (HHS) will remove some obstacles that limit the ability of doctors to prescribe buprenorphine for patients who are addicted to heroin or prescription painkillers, The Huffington Post reports.

Under current regulations, doctors who are certified to prescribe buprenorphine (sold as Suboxone) are allowed to write prescriptions for up to 30 patients initially. After one year, they can request authorization to prescribe up to a maximum of 100 patients. The HHS will develop revisions to the regulations “to provide a balance between expanding the supply of this important treatment, encouraging the use of evidence-based [medication-assisted treatment], and minimizing the risk of drug diversion,” the department said in a press release.

In areas hard hit by opioid addiction, doctors’ buprenorphine treatment slots can fill up quickly, the article notes. One recent study found buprenorphine treatment is unavailable in U.S. counties where more than 30 million people live.

Full story of prescibing Bupreonorphine for opioid addiction at drugfree.org